Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.49 USD | +8.76% | +12.88% | +20.16% |
Apr. 23 | Averoa Seeks EU Approval for Chronic Kidney Disease Drug | MT |
Apr. 16 | Akebia Therapeutics, Inc. and STA Pharmaceutical Hong Kong Limited Enters into Second Amendment to the Supply Agreement | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+20.16% | 312M | |
+9.15% | 106B | |
-1.08% | 104B | |
+5.79% | 23.25B | |
-11.55% | 22.5B | |
-7.01% | 18.7B | |
-37.08% | 17.95B | |
-9.91% | 16.99B | |
+7.55% | 14.26B | |
+40.04% | 12.76B |
- Stock Market
- Equities
- AKBA Stock
- News Akebia Therapeutics, Inc.
- Mizuho Securities Downgrades Akebia Therapeutics to Neutral From Buy, Adjusts Price Target to $2 From $6